These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 31060542)

  • 1. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
    Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
    Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.
    Shahabi A; Lewinger JP; Ren J; April C; Sherrod AE; Hacia JG; Daneshmand S; Gill I; Pinski JK; Fan JB; Stern MC
    Prostate; 2016 Oct; 76(14):1239-56. PubMed ID: 27272349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
    Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
    Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
    Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
    PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
    Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
    Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
    Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
    Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
    Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL
    Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
    Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
    Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.